首页> 美国卫生研究院文献>Clinical Cardiology >The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis
【2h】

The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis

机译:老年人舒张性心力衰竭的典型形式:野生型运甲状腺素蛋白心脏淀粉样变性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Wild‐type transthyretin cardiac amyloidosis (ATTRwt) is now recognized as a common cause of heart failure with preserved ejection fraction (HFpEF). In this review, we aim to describe the unique epidemiologic, pathophysiologic, and clinical features associated with ATTwt cardiac amyloidosis. Compared to other etiologies of HFpEF, ATTRwt cardiac amyloidosis affects almost exclusively older adults, demonstrating a characteristic age‐dependent penetrance that impacts both the diagnosis and treatment of the disease. In addition, ATTR cardiac amyloidosis demonstrates a unique pathophysiology in contrast to other etiologies of HFpEF, which results in a characteristic phenotype that can raise suspicion for ATTRwt cardiac amyloid in the appropriate demographic. With these distinguishing features in mind, we aim to describe the specific signs, symptoms, and imaging characteristics associated with ATTRwt cardiac amyloidosis, including the role of nuclear scintigraphy that has essentially eliminated the need for biopsy in most patients with suspected disease. Finally, we review the evidence behind the available therapeutic agents, as well as those under investigation, which will change the way we manage older patients with ATTRwt cardiac amyloidosis in the coming years.
机译:野生型运甲状腺素蛋白心脏淀粉样变性病(ATTRwt)现在被认为是射血分数(HFpEF)保持不变的心力衰竭的常见原因。在这篇综述中,我们旨在描述与ATTwt心脏淀粉样变性有关的独特流行病学,病理生理学和临床特征。与HFpEF的其他病因相比,ATTRwt心脏淀粉样变性几乎仅影响老年人,这表明特征性的年龄依赖性外显率会影响该疾病的诊断和治疗。此外,与HFpEF的其他病因相比,ATTR心脏淀粉样变表现出独特的病理生理学,这导致特征表型可能会在适当的人群中引起对ATTRwt心脏淀粉样蛋白的怀疑。考虑到这些区别特征,我们旨在描述与ATTRwt心脏淀粉样变性有关的特定体征,症状和影像学特征,包括核闪烁显像的作用,该显像法基本上消除了大多数疑似疾病患者的活检的必要性。最后,我们回顾了现有治疗剂以及正在研究的治疗剂背后的证据,这些证据将在未来几年内改变我们治疗老年ATTRwt心脏淀粉样变性患者的方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号